Intragastric Balloon Market Size

Intragastric Balloon Market Analysis

The intragastric balloon market is expected to register a CAGR of 9.1% over the forecast period.

• The outbreak of the COVID-19 pandemic impacted the intragastric balloon market. People with an underlying condition such as obesity were at greater risk during the COVID-19 pandemic. For instance, as per the data published by the World Health Organization (WHO), in 2020, more than 1.9 billion adults, 18 years and older, were overweight. Among them, over 650.0 million were obese. Similarly, as per the data published by the CDC in March 2021, around 30.2% of the total COVID-19 hospitalizations were attributed to obesity. In addition, during COVID-19, the obesity rate increased exponentially. 
• For instance, according to the research article published by the European Journal of Nutrition in December 2021, the rate of obesity increased during the pandemic due to a change in lifestyle and a decrease in exercise practice among people, as they avoided gym and yoga classes due to the social distancing protocols. Thus, such an increased rate of obesity surged the demand for intragastric balloons during the pandemic, and thus, the market witnessed positive growth during COVID-19 and is expected to continue the upward trend over the forecast period.
• The rising adoption of minimally invasive treatment and the increasing prevalence of obesity are the major factors propelling market growth. For instance, according to the report published by the World Health Organization (WHO) in March 2022, more than 1.0 billion people worldwide are obese, of which 650 million adults, 340 million adolescents, and 39 million children. The same source also stated that by 2025, approximately 167 million people will be obese, including adults and children. Intragastric balloons are widely used for the treatment of obesity and offer effective results. 
• For instance, according to the National Center for Biotechnology Information (NCBI) study published in January 2023, intragastric balloons serve as a minimally invasive tool to combat the obesity pandemic. There are multiple intragastric balloons approved for the United States and European markets. Indications in the United States include a BMI of 30 to 35 kg/m^2 but a BMI of 27 to 35 kg/m^2 in Europe. Thus, increasing cases of obesity across the globe are expected to positively impact market growth.
• The increasing preference towards minimally invasive treatment and product launches by the key players are also driving market growth. For instance, according to the NCBI research article published in February 2022, in the studied population, about 57.0% of the patients who preferred minimally invasive treatment made their decision under the influence of the healthcare professionals as they recommended minimally invasive treatment and reported less perceived disadvantages following their treatment. Such studies depict the higher acceptance of healthcare professionals and patients of minimally invasive procedures over traditional procedures. Furthermore, in September 2022, Allurion Technologies, the United States-based medical device manufacturer, launched its weight loss solution, a swallowable gastric balloon, in India. The product claims to reduce weight by 10-15% on average within 16 weeks. Therefore, increasing adoption of minimally invasive treatments and product launches are anticipated to propel the market growth over the forecast period.
• However, the side effects or complications associated with intragastric balloons may hamper the market growth over the forecast period.